Franck E. Nicolini

4.9k total citations · 1 hit paper
64 papers, 1.7k citations indexed

About

Franck E. Nicolini is a scholar working on Hematology, Genetics and Rheumatology. According to data from OpenAlex, Franck E. Nicolini has authored 64 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 63 papers in Hematology, 55 papers in Genetics and 17 papers in Rheumatology. Recurrent topics in Franck E. Nicolini's work include Chronic Myeloid Leukemia Treatments (59 papers), Chronic Lymphocytic Leukemia Research (52 papers) and Eosinophilic Disorders and Syndromes (17 papers). Franck E. Nicolini is often cited by papers focused on Chronic Myeloid Leukemia Treatments (59 papers), Chronic Lymphocytic Leukemia Research (52 papers) and Eosinophilic Disorders and Syndromes (17 papers). Franck E. Nicolini collaborates with scholars based in France, United States and Germany. Franck E. Nicolini's co-authors include Jörge E. Cortes, Hagop M. Kantarjian, Andreas Hochhaus, Dong‐Wook Kim, Michele Baccarani, Giovanni Martinelli, M. Brigid Bradley‐Garelik, Edo Vellenga, María Soledad Undurraga and Juan Julio Kassack Ipiña and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Annals of Internal Medicine.

In The Last Decade

Franck E. Nicolini

60 papers receiving 1.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)

2011 441 citations Hagop M. Kantarjian, Jörge E. Cortes et al. Blood profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Franck E. Nicolini France	19	1.5k	1.2k	697	253	209	64	1.7k
Gabriele Gugliotta Italy	20	857 0.6×	704 0.6×	377 0.5×	160 0.6×	101 0.5×	60	1.1k
Tanja Lahaye Germany	12	1.2k 0.8×	1.0k 0.8×	762 1.1×	141 0.6×	123 0.6×	22	1.4k
Pierre Laneuville Canada	18	747 0.5×	487 0.4×	229 0.3×	297 1.2×	169 0.8×	57	1.1k
Benjamin Hanfstein Germany	11	983 0.7×	784 0.6×	562 0.8×	139 0.5×	114 0.5×	28	1.1k
Enrico Montefusco Italy	21	985 0.7×	782 0.6×	436 0.6×	250 1.0×	129 0.6×	68	1.4k
Susanne Herndlhofer Austria	16	756 0.5×	443 0.4×	267 0.4×	266 1.1×	68 0.3×	41	1.1k
Niove E. Jordanides United Kingdom	9	864 0.6×	636 0.5×	366 0.5×	221 0.9×	53 0.3×	13	1.2k
Ya‐Zhen Qin China	23	1.5k 1.0×	472 0.4×	172 0.2×	305 1.2×	639 3.1×	153	1.9k
Jean-Luc Laı̈ France	14	1.1k 0.8×	715 0.6×	297 0.4×	234 0.9×	168 0.8×	33	1.4k
Virginia Kelly United States	16	453 0.3×	624 0.5×	173 0.2×	394 1.6×	87 0.4×	34	1.2k

Countries citing papers authored by Franck E. Nicolini

Since Specialization

Citations

This map shows the geographic impact of Franck E. Nicolini's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Franck E. Nicolini with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Franck E. Nicolini more than expected).

Fields of papers citing papers by Franck E. Nicolini

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Franck E. Nicolini. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Franck E. Nicolini. The network helps show where Franck E. Nicolini may publish in the future.

Co-authorship network of co-authors of Franck E. Nicolini

This figure shows the co-authorship network connecting the top 25 collaborators of Franck E. Nicolini. A scholar is included among the top collaborators of Franck E. Nicolini based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Franck E. Nicolini. Franck E. Nicolini is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Johnson‐Ansah, Hyacinthe, Anaïs R. Briant, A Charbonnier, et al.. (2023). Interleukin 10 (IL10) and IL15 Significantly Decreased in Chronic Myeloid Leukemia Patients Presenting with Tyrosine Kinase Inhibitor (TKI) Withdrawal Syndrome (TWS). Results from the Prospective, Explorative and Multicenter « Kiwis » Study Designed for TWS. Clinicaltrial.Gov ID: NCT03996096; Study Number: 18-206. Blood. 142(Supplement 1). 6335–6335. 1 indexed citations

Pfirrmann, Markus, François‐Xavier Mahon, Stéphanie Dulucq, et al.. (2023). S155: PROGNOSTIC FACTORS FOR 3-YEAR MAJOR MOLECULAR RESPONSE MAINTENANCE IN CHRONIC MYELOID LEUKAEMIA PATIENTS IN THE EUROPEAN STOP KINASE INHIBITORS (EURO-SKI) TRIAL. HemaSphere. 7(S3). e230884b–e230884b.

Réa, Delphine, Emmanuel Messas, Tristan Mirault, & Franck E. Nicolini. (2022). Recommandations 2022 du groupe Fi-LMC pour la gestion du risque d’événements cardiovasculaires sous ponatinib dans la leucémie myéloïde chronique. Bulletin du Cancer. 109(7-8). 862–872. 1 indexed citations

Hughes, Timothy P., Nelma Cristina D. Clementino, Jeffrey H. Lipton, et al.. (2021). Long-term treatment-free remission in patients with chronic myeloid leukemia after second-line nilotinib: ENESTop 5-year update. Leukemia. 35(6). 1631–1642. 26 indexed citations

Hayette, Sandrine, Maxime Vallée, Claire Bardel, et al.. (2021). Performances of Targeted RNA Sequencing for the Analysis of Fusion Transcripts, Gene Mutation, and Expression in Hematological Malignancies. HemaSphere. 5(2). e522–e522. 5 indexed citations

Kumar, Rahul, Raquel Pereira, Valentina R. Minciacchi, et al.. (2020). Specific, targetable interactions with the microenvironment influence imatinib-resistant chronic myeloid leukemia. Leukemia. 34(8). 2087–2101. 29 indexed citations

Nicolini, Franck E., Stéphanie Dulucq, Joëlle Guilhot, Gabriel Étienne, & François‐Xavier Mahon. (2018). The Evaluation of Residual Disease By Digital PCR, and TKI Duration Are Critical Predictive Factors for Molecular Recurrence after for Stopping Imatinib First-Line in Chronic Phase CML Patients: Results of the STIM2 Study.. Blood. 132(Supplement 1). 462–462. 7 indexed citations

Nicolini, Franck E., Vincent Alcazer, Pascale Cony‐Makhoul, et al.. (2018). Long-term follow-up of de novo chronic phase chronic myelogenous leukemia patients on front-line imatinib. Experimental Hematology. 64. 97–105.e4. 6 indexed citations

Heiblig, Maël, Delphine Réa, Marie‐Lorraine Chrétien, et al.. (2018). Ponatinib evaluation and safety in real-life chronic myelogenous leukemia patients failing more than two tyrosine kinase inhibitors: the PEARL observational study. Experimental Hematology. 67. 41–48. 31 indexed citations

10.

Lepoutre, Thomas, et al.. (2016). BCR-ABL transcript variations in chronic phase chronic myelogenous leukemia patients on imatinib first-line: Possible role of the autologous immune system. OncoImmunology. 5(5). e1122159–e1122159. 4 indexed citations

11.

Lepoutre, Thomas, et al.. (2015). Implication of the Autologous Immune System in BCR–ABL Transcript Variations in Chronic Myelogenous Leukemia Patients Treated with Imatinib. Cancer Research. 75(19). 4053–4062. 32 indexed citations

12.

Heiblig, Maël, Mohamed Sobh, & Franck E. Nicolini. (2014). Subcutaneous omacetaxine mepesuccinate in patients with chronic myeloid leukemia in tyrosine kinase inhibitor-resistant patients: Review and perspectives. Leukemia Research. 38(10). 1145–1153. 18 indexed citations

13.

Wallet, Hélène Labussière, Mohamad Sobh, Marie Robin, et al.. (2013). First application of the EBMT risk score in double umbilical cord blood transplantation for hematologic malignancies: Significant impact on different outcomes. Experimental Hematology. 42(3). 161–162. 5 indexed citations

14.

Cortes, Jörge E., Franck E. Nicolini, Meir Wetzler, et al.. (2013). Subcutaneous Omacetaxine Mepesuccinate in Patients With Chronic-Phase Chronic Myeloid Leukemia Previously Treated With 2 or More Tyrosine Kinase Inhibitors Including Imatinib. Clinical Lymphoma Myeloma & Leukemia. 13(5). 584–591. 39 indexed citations

15.

Cortes, Jörge E., Jeff H. Lipton, Delphine Réa, et al.. (2012). Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation. Blood. 120(13). 2573–2580. 89 indexed citations

16.

Wetzler, Meir, Hagop M. Kantarjian, Franck E. Nicolini, et al.. (2012). Pooled safety analysis of omacetaxine mepesuccinate in patients with chronic myeloid leukemia (CML) resistant to tyrosine-kinase inhibitors (TKIs).. Journal of Clinical Oncology. 30(15_suppl). 6604–6604. 6 indexed citations

17.

Nicolini, Franck E., Anna Turkina, Zhixiang Shen, et al.. (2011). Expanding Nilotinib Access in Clinical Trials (ENACT). Cancer. 118(1). 118–126. 48 indexed citations

18.

Hayette, Sandrine, Kaddour Chabane, Mauricette Michallet, et al.. (2010). Longitudinal studies of SRC family kinases in imatinib- and dasatinib-resistant chronic myelogenous leukemia patients. Leukemia Research. 35(1). 38–43. 15 indexed citations

19.

Nicolini, Franck E., Wei Zhou, Giovanni Martinelli, et al.. (2009). Impact of Allogeneic Stem Cell Transplantation as Salvage Therapy After T315I Mutation Detection in Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (ALL) Patients.. Blood. 114(22). 645–645. 3 indexed citations

20.

Nicolini, Franck E., Sandrine Hayette, Sélim Corm, et al.. (2007). Clinical outcome of 27 imatinib mesylate-resistant chronic myelogenous leukemia patients harboring a T315I BCR-ABL mutation. Haematologica. 92(9). 1238–1241. 51 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact